EdgarLookup

Artiva Biotherapeutics, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Artiva Biotherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2024 $251.0K Nov 12, 2025
Q2 2025 Jun 30, 2024 $251.0K Aug 6, 2025
Q1 2025 Mar 31, 2024 $251.0K May 8, 2025
Q3 2024 Sep 30, 2023 $26.66M Nov 12, 2024
Q2 2024 Jun 30, 2023 $3.50M Aug 29, 2024

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2024 Sep 30, 2023 $26.66M Nov 12, 2024
Q2 2024 Jun 30, 2023 $3.50M Aug 29, 2024

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($21.53M) Nov 12, 2025
Q3 2025 Jun 30, 2025 ($21.25M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($21.25M) Aug 6, 2025
Q3 2025 Mar 31, 2025 ($20.31M) Nov 12, 2025
Q2 2025 Mar 31, 2025 ($20.31M) Aug 6, 2025
Q1 2025 Mar 31, 2025 ($20.31M) May 8, 2025
Q3 2025 Sep 30, 2024 ($17.47M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($17.84M) Aug 6, 2025
Q3 2025 Jun 30, 2024 ($17.84M) Nov 12, 2025
Q3 2025 Mar 31, 2024 ($13.96M) Nov 12, 2025
Q2 2025 Mar 31, 2024 ($13.96M) Aug 6, 2025
Q1 2025 Mar 31, 2024 ($13.96M) May 8, 2025
Q3 2024 Sep 30, 2023 $11.28M Nov 12, 2024
Q2 2024 Jun 30, 2023 ($11.28M) Aug 29, 2024
Q3 2024 Jun 30, 2023 ($11.28M) Nov 12, 2024
Q3 2024 Mar 31, 2023 ($16.72M) Nov 12, 2024
Q2 2024 Mar 31, 2023 ($16.72M) Aug 29, 2024

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($22.90M) Nov 12, 2025
Q2 2025 Jun 30, 2025 ($22.81M) Aug 6, 2025
Q1 2025 Mar 31, 2025 ($22.17M) May 8, 2025
Q3 2025 Sep 30, 2024 ($18.34M) Nov 12, 2025
Q2 2025 Jun 30, 2024 ($16.19M) Aug 6, 2025
Q1 2025 Mar 31, 2024 ($14.49M) May 8, 2025
Q3 2024 Sep 30, 2023 $10.81M Nov 12, 2024
Q2 2024 Jun 30, 2023 ($11.82M) Aug 29, 2024